Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Biotech Investing

Where the AstraZeneca Stock Price Is Headed After ASCO 2015

By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM • June 3, 2015

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Astrazeneca stock priceThe AstraZeneca stock price is hovering near $68 after the company presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago this week.

ASCO is an annual event that's attended by 30,000 people and hosts more than 4,000 presentations. This year's meeting began on May 29 and ran through June 2.

It's the premiere event for companies developing cancer drugs. And every year, some cancer stocks get a serious ASCO-related lift.

Money Morning's Executive Editor Bill Patalon calls it the "ASCO Effect." Last year, he recommended Bristol Meyers Squibb Co. (NYSE: BMY) and it climbed 36.5% in the following year.

"The general run-up in oncology stocks is related to the heightened general focus on cancer-related medicine," Patalon said last week. "And there's usually a really big pop in the shares of several companies whose researchers present important papers at the conference."

So the question for investors is - will the AstraZeneca Plc. (NYSE ADR: AZN) stock price see a post-ASCO bump?

The company was one of the headliners at ASCO, and here's what we learned...

AstraZeneca's (AZN) Big ASCO Update

AstraZeneca officials held an investor science event during ASCO this week and provided an update on their immune-oncology pipeline.
Immuno-oncology was a major theme of the 2014 ASCO event, according to Patalon. It's a new category of drugs that use the body's own immune cells to target a variety of cancers. The market potential is huge, and Patalon described it as the biotech sector's version of "the California Gold Rush."

AstraZeneca Plc. (NYSE: AZN)

Recent Price: $67.40

Market Cap: $84.6 billion

2015 EPS Estimate: $4.21

Operating Margin: 13.5%

Beta: 0.78

This week, AstraZeneca announced two of its new immune-oncology drug candidates had seen exciting results. The drugs, MEDI4736 and tremelimumab, are being tested for treatment of non-small-cell lung cancer.

The company reported increased response rates in patients with several different types of tumors who have been taking the combination of drugs. AstraZeneca will now advance the combination into phase 3 trials.

Completing phase 2 and phase 3 FDA trials can be a major catalyst for biotech stocks. Investors will want to keep a close eye on this combination as it heads into phase 3 trials.

Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter

Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…

Claim My Free Report

Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments


Latest News

September 22, 2023 • By Shah Gilani

earnings
Why the Fed's "Higher for Longer" Message on Interest Rates is Bogus

September 22, 2023 • By Tom Gentile

This is the Top 'Worst-in-Breed' Stock Heading into October

September 22, 2023 • By Garrett Baldwin

Will The Fed Bankrupt the Tooth Fairy?
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz